Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
27 nov. 2023 07h30 HE
|
Annovis Bio Inc.
BERWYN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s...
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
08 nov. 2023 17h00 HE
|
Annovis Bio Inc.
BERWYN, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases,...
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
12 oct. 2023 08h02 HE
|
Annovis Bio Inc.
BERWYN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today...
Annovis Bio to Present at the BIO CEO & Investor Digital Conference
16 févr. 2021 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
17 déc. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Showcases its Unique Approach to Alzheimer’s at the New York Academy of Sciences
15 déc. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020
07 déc. 2020 16h05 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference
03 déc. 2020 09h15 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium
16 nov. 2020 09h15 HE
|
Annovis Bio Inc.
BERWYN, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases
12 nov. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...